Barclays Reiterates €100.00 Price Target for Bayer (BAYN)

Barclays set a €100.00 ($116.28) target price on Bayer (FRA:BAYN) in a research report sent to investors on Thursday morning. The firm currently has a buy rating on the healthcare company’s stock.

A number of other brokerages also recently commented on BAYN. Sanford C. Bernstein set a €120.00 ($139.53) target price on Bayer and gave the company a buy rating in a research note on Monday, June 4th. Jefferies Financial Group set a €123.00 ($143.02) target price on Bayer and gave the company a buy rating in a research note on Monday, June 4th. UBS Group set a €130.00 ($151.16) target price on Bayer and gave the company a buy rating in a research note on Friday, June 1st. Warburg Research set a €118.00 ($137.21) target price on Bayer and gave the company a neutral rating in a research note on Monday, June 4th. Finally, Kepler Capital Markets set a €104.00 ($120.93) target price on Bayer and gave the company a neutral rating in a research note on Monday, June 4th. Ten research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the stock. Bayer currently has an average rating of Buy and a consensus price target of €101.36 ($117.86).

Shares of FRA BAYN opened at €71.82 ($83.51) on Thursday. Bayer has a one year low of €91.58 ($106.49) and a one year high of €123.82 ($143.98).

Bayer Company Profile

Bayer Aktiengesellschaft operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, Crop Science, and Animal Health segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents.

Further Reading: Risk Tolerance and Your Investment Decisions

Analyst Recommendations for Bayer (FRA:BAYN)

Receive News & Ratings for Bayer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit